Clinical Trial Update: Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating a three-drug regimen of polatuzumab vedotin, rituximab, and orelabrutinib for elderly, frail patients with treatment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Affiliated Hospital of Nantong University | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING